TG THERAPEUTICS, INC.
Close on Oct 19, 2026
- Market cap
- $8.38B
- P/E (TTM)
- 19.5
- Dividend yield
- –
Earnings
Next report expected Nov 2, 2026, before market open (estimated from past report dates)
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q2 FY2026 Ended Jun 30, 2026 | Aug 3, 2026 | Before market open | $240.30M | $0.05 | – |
| Q1 FY2026 Ended Mar 31, 2026 | May 6, 2026 | Before market open | $204.92M | $0.12 | – |
| Q4 FY2025 Ended Dec 31, 2025 | Feb 26, 2026 | Before market open | $192.57M | $0.14 | – |
| Q3 FY2025 Ended Sep 30, 2025 | Nov 3, 2025 | Before market open | $161.70M | $2.43 | – |
| Q2 FY2025 Ended Jun 30, 2025 | Aug 4, 2025 | Before market open | $141.10M | $0.17 | – |
| Q1 FY2025 Ended Mar 31, 2025 | May 5, 2025 | Before market open | – | – | – |
| Q4 FY2024 Ended Dec 31, 2024 | Mar 3, 2025 | Before market open | $108.19M | $0.15 | – |
| Q3 FY2024 Ended Sep 30, 2024 | Nov 4, 2024 | Before market open | – | – | – |
| Q2 FY2024 Ended Jun 30, 2024 | Aug 6, 2024 | Before market open | $73.47M | $0.04 | – |
| Q1 FY2024 Ended Mar 31, 2024 | May 1, 2024 | Before market open | – | – | – |
| Q4 FY2023 Ended Dec 31, 2023 | Feb 28, 2024 | Before market open | – | – | – |
Company guidance
Outlook given with results on Aug 3, 2026, compared with the previous outlook
| Measure | Period | Guidance | vs. prior |
|---|---|---|---|
| target operating expensenon-GAAP | full year 2026 | $350.00M to $400.00M | Raised |
| total global revenue | full year 2026 | $950.00M | Raised |
| BRIUMVI U.S. net product revenue | full year 2026 | $890.00M to $905.00M | Lowered |
Figures and the sentence they come from are taken from the company's earnings release. Hover a measure to read the source sentence.
Press releases
Announcements Tg Therapeutics filed with the SEC
TG Therapeutics Reports Second Quarter 2026 Financial Results and Raises BRIUMVI ® Revenue Guidance
Results of operations · EX-99.1 to Form 8-K
TG Therapeutics Announces Positive Results from Phase 1 Trial Evaluating Subcutaneous BRIUMVI ® (ublituximab-xiiy)
Other events · EX-99.1 to Form 8-K
TG Therapeutics Announces Positive Topline Results from Phase 3 ENHANCE Trial
Other events · EX-99.1 to Form 8-K
TG Therapeutics Reports First Quarter 2026 Financial Results and Raises BRIUMVI Revenue Guidance
Results of operations · EX-99.1 to Form 8-K
TG Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Raises BRIUMVI Revenue Guidance
Results of operations · EX-99.1 to Form 8-K
TG Therapeutics Provides Preliminary Fourth Quarter and Full Year 2025 Net Product Revenue and 2026 Revenue Guidance and Anticipated Development Milestones
Regulation FD disclosure · EX-99.1 to Form 8-K
TG Therapeutics Reports Third Quarter 2025 Financial Results and Raises BRIUMVI Revenue Guidance
Results of operations · EX-99.1 to Form 8-K
TG Therapeutics Reports Second Quarter 2025 Financial Results and Raises BRIUMVI Revenue Guidance
Results of operations · EX-99.1 to Form 8-K
TG Therapeutics Reports First Quarter 2025 Financial Results and Raises BRIUMVI Full Year Revenue Guidance
Results of operations · EX-99.1 to Form 8-K
TG Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2024 Financial Results
Results of operations · EX-99.1 to Form 8-K
TG Therapeutics Provides Preliminary Fourth Quarter and Full Year 2024 Net Revenue and 2025 Anticipated Development Milestones
Regulation FD disclosure · EX-99.1 to Form 8-K
TG Therapeutics Reports Third Quarter 2024 Financial Results and Raises BRIUMVI ® (ublituximab-xiiy) Full Year Revenue Guidance
Results of operations · EX-99.1 to Form 8-K
TG Therapeutics Reports Second Quarter 2024 Financial Results and Raises BRIUMVI ® (ublituximab-xiiy) Full Year Revenue Guidance
Material agreement · Agreement terminated · Results of operations · Other events · EX-99.1 to Form 8-K
TG Therapeutics Provides Business Update and Reports First Quarter 2024 Financial Results
Results of operations · EX-99.1 to Form 8-K
TG Therapeutics Provides Business Update and Reports Fourth Quarter and Year-End 2023 Financial Results
Results of operations · EX-99.1 to Form 8-K
TG Therapeutics Provides Preliminary Fourth Quarter and Full Year 2023 Net Revenue and 2024 Anticipated Milestones
Material agreement · Regulation FD disclosure · EX-99.1 to Form 8-K
TG Therapeutics Provides Business Update and Reports Third Quarter 2023 Financial Results
Results of operations · EX-99.1 to Form 8-K
TG Therapeutics Provides Business Update and Reports Second Quarter 2023 Financial Results
Material agreement · Results of operations · EX-99.1 to Form 8-K
TG Therapeutics Provides Business Update and Reports First Quarter 2023 Financial Results
Results of operations · EX-99.1 to Form 8-K
TG Therapeutics Provides Business Update and Reports Fourth Quarter and Year-End 2022 Financial Results
Results of operations · EX-99.1 to Form 8-K
TG Therapeutics Announces FDA Approval of BRIUMVI™ (ublituximab-xiiy)
Other events · EX-99.1 to Form 8-K
TG Therapeutics Provides Business Update and Reports Third Quarter 2022 Financial Results
Results of operations · EX-99.1 to Form 8-K
TG Therapeutics Provides Business Update and Reports Second Quarter 2022 Financial Results
Results of operations · EX-99.1 to Form 8-K
TG Therapeutics Announces Voluntary Withdrawal of the BLA/sNDA for U2 to Treat Patients with CLL and SLL
Other events · EX-99.1 to Form 8-K
TG Therapeutics Provides Business Update and Reports Fourth Quarter and Year-End 2021 Financial Results
Results of operations · EX-99.1 to Form 8-K
TG Therapeutics Provides Regulatory Update
Other events · EX-99.1 to Form 8-K
TG Therapeutics Provides Business Update and Reports Third Quarter 2021 Financial Results
Results of operations · EX-99.1 to Form 8-K